More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced. Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
New information regarding the efficiency and effectiveness of different oscillating positive expiratory pressure devices was presented at CHEST 2017 in Toronto, Canada.
While it’s one of the most anticipated seasons of the year, summer can also be the most difficult season for Canadians living with COPD (chronic obstructive pulmonary disease). We want to help you make the most of it! Here’s what you need to know about summer, and how you can enjoy yours this year.
Living a full life with Chronic Obstructive Pulmonary Disease (COPD) is more accessible than ever before with today’s online resources. Whether you’re looking for in-depth tutorials, facts, or simple tips on self-management, the web offers information at your fingertips. Here’s a few of our favourite bookmark-worthy websites for you!
Living a full life with Chronic Obstructive Pulmonary Disease (COPD) is more accessible than ever before with today’s online resources. Whether you’re looking for in-depth tutorials, facts, or simple tips on self-management, the web offers information at your fingertips. Here’s a few of our favourite bookmark-worthy websites for you!
Watch Community Respiratory Therapists Jacqueline Turvey and Joanne Terry for an interactive discussion on the benefits of Airway Clearance Therapy (ACT), and why this non-pharmacological treatment should be integrated into the action plans of patients dealing with COPD.
Join Dr. Douglas Mack and Dr. Mariam Hanna as they discuss the importance of asthma control in today’s world, as well as the shift to virtual appointments including tools and tips to optimize virtual asthma assessments. Please see a recording of the session below.
The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.
Expert insights from UK respiratory specialists and school nurses on fall and winter asthma triggers and advancements in asthma care and innovative technologies supporting better management among children and adolescents.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
This laboratory study compared the performance of four different OPEP devices, each utilizing distinctly different mechanisms to generate oscillatory pressure.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
This laboratory and clinical overview demonstrates appreciable differences in pressure pulse waveforms for differing OPEP devices and then links these for the leading laboratory performing device into reported airway physiological changes and improved clinical outcomes.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
Short-acting beta2 agonist (SABA) monotherapy is typically required to provide as needed short term relief of bronchoconstriction. The salbutamol EasyHaler† DPI has recently become available in the UK as an alternative to delivery by pressurized metered-dose inhaler. Our study evaluated delivery from this DPI at different inhalation flow rates.
Chronic Obstructive Pulmonary Disease (COPD) affects around 251 million people globally.1 It is a term that covers two types of chronic (long-term) diseases where the airways in the lungs become “obstructed” or partly blocked.
